Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other 1Breast 1

Conditions

Anatomic Stage I Breast Cancer AJCC v8 1

Interventions

Trastuzumab 732Paclitaxel 695Cyclophosphamide 647Docetaxel 560Capecitabine 486Letrozole 437Fulvestrant 400Carboplatin 398Doxorubicin 341Tamoxifen 308Anastrozole 279pembrolizumab 274exemestane 258Epirubicin 251pertuzumab 240Radiotherapy 239palbociclib 224Bevacizumab 222Gemcitabine 215Vinorelbine 197Lapatinib 181130-nm albumin-bound paclitaxel 172Magnetic Resonance Spectroscopy 164Albumin-Bound Paclitaxel 157eribulin 154Surveys and Questionnaires 152Exercise 151Drug Therapy 141Taxes 134Fluorouracil 133

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
lorcaserin × Breast × Clear all
NCT04205071 2021-01-19

Lorcaserin in Treating Chemotherapy-Induced Peripheral Neuropathy in Patients With Stage I-IV Gastrointestinal or Breast Cancer

Ohio State University Comprehensive Cancer Center

Phase 1 Withdrawn
BreastOther

Anatomic Stage I Breast Cancer AJCC v8

Data powered by HemOnc (CC BY 4.0) Colophon âš¡